Blog

A macrodose is a higher dose of a psychedelic taken to produce full, noticeable effects, in contrast to microdosing, which aims for sub-perceptual effects. People often describe macrodosing experiences in levels: Level 1 mild shifts in mood and sensory depth; Level 2 brighter colors, slight visual movement, simple closed-eye patterns; Level 3 clear visual distortions […]

Psilocybin therapy may help some people make healthier choices by creating space for reflection and value clarity. In a supportive setting, people can recognize unhelpful patterns and set intentions that align better with sleep, nutrition, movement, relationships, and substance use. When insights are followed by integration work, small experiments become easier to start and maintain. […]

Yes. We welcome Belgian participants. Our open truffle ceremonies are available to anyone who registers and are not specific to one country. Many people from Belgium choose to join in the Netherlands. We host at our locations in Schiedam, Den Bosch, or Noordwijk, or at your chosen venue within Dutch borders. You can find current […]

Combining regression therapy with psilocybin truffles carries a key risk: heightened suggestibility. In that state, leading or loaded questions can seed confabulation, making it easier for false memories to form. The experience can also be emotionally overwhelming. Intense imagery and symbolism may be misread as literal memory, and strong feelings can blur the line between […]

Yes, some people find that SSRIs like citalopram can blunt the effects of psilocybin, sometimes even after stopping. Experiences vary a lot, from noticeably reduced visuals or emotional depth to almost no effect, while others report no change at all. A common explanation is that long term SSRI use may reduce sensitivity at serotonin 5-HT2A […]

I cannot verify a specific date here. For the latest confirmed date, check the schedule on this Q&A page: next psychedelic ceremony. If you have your own group, a custom date is often possible. For groups larger than three, contact the organizers to arrange it manually. If you are solo or a smaller group, ask […]

People call me Marcel Trip because about 16 years ago I became known locally as the guy you could go on a mushroom trip with. Friends saved my number as “Marcel Trip,” and the nickname stuck. Along the way I picked up other playful nicknames like MarceLSD, tripgozer, and truffelman. It’s just a nickname, not […]

Short answer: I am not aware of well documented direct interactions between psilocybin and insulin (including Levemir), metformin, dapagliflozin/Forxiga, pantoprazole, rosuvastatin, or low-dose aspirin. Still, a session can change appetite, food intake, and activity, so glucose may swing; plan monitoring. With SGLT2s like dapagliflozin, keep up fluids to reduce dehydration risk. Psilocybin is reported to […]

Short answer: both matter, yet a guide’s inner state often matters at least as much as credentials. Research in psychotherapy and psychedelic settings suggests that alliance, set, and setting are strongly linked to how sessions are experienced and integrated. I cannot verify every individual study, but this pattern appears consistently across the literature. Why this […]

Short answer: there is no convincing evidence that psilocybin from mushrooms or truffles raises GLP-1 or acts like a GLP-1 agonist. The appetite drop many people notice during a psychedelic experience is more likely tied to serotonergic effects, especially 5-HT2A activation, which can shift attention away from food and reduce food reward. Both GLP-1 drugs […]

Short answer: early evidence says yes. In adults with major depression and suicidal ideation, a randomized trial in the American Journal of Psychiatry reported that starting low-dose buprenorphine about 48 hours after a single ketamine infusion was associated with a larger and more sustained reduction in suicidal thoughts over four weeks compared with ketamine plus […]

Some people choose LSD therapy over psilocybin not because it is more effective, but because of how the experience feels. The clinical literature is currently larger for psilocybin in areas like depression, end-of-life anxiety, addiction, and PTSD, which reflects research focus and session logistics, not a universal advantage. People often describe psilocybin as inward and […]